We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AnaSpec Introduces Pancreatic ß-Cells Specific Antibodies
Product News

AnaSpec Introduces Pancreatic ß-Cells Specific Antibodies

AnaSpec Introduces Pancreatic ß-Cells Specific Antibodies
Product News

AnaSpec Introduces Pancreatic ß-Cells Specific Antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AnaSpec Introduces Pancreatic ß-Cells Specific Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaSpec has announced the release of three antibodies (two monoclonal and one polyclonal) against FXYD2γa.

FXYD2γa is a regulating subunit of the NA+-K+-ATPase and has been identified as a unique and specific pancreatic beta cell surface biomarker.

In individuals with Type 1 diabetes or in pancreatic sections of streptozotocin-treated Macacus cynomolgus monkeys, loss of FXYD2γa has been closely correlated with a loss of insulin positive cells.

Anti-hFXYD2γa antibodies are purified antibodies reacting with an 11 amino acid residue peptide of FXYD2γa.

Monoclonal anti-FXYD2γa antibodies from Clone 4F9G9 show high specificity towards FXYD2γa beta-cell biomarker while monoclonal anti-FXYD2γa antibodies from Clone 3C1D10 show high sensitivity towards FXYD2γa beta-cell biomarker.

A rabbit polyclonal anti-hFXYD2γa antibody is also available (see Table 1). These antibodies can be used for beta cell specific targeting and non-invasive imaging.

The use of targeting strategies against the biomarker (FXYD2γa) allows early identification of beta cell and the follow up of therapies for diabetes patients.

Advertisement